Following major outlays in China and the U.S., Eli Lilly has announced plans to boost capacity at its sole Japanese production site to keep pace with the growing demand for metabolic treatments.
Strengthening local supply infrastructure
On March 12, Eli Lilly unveiled a 20 billion yen (nearly $126 million) expansion at its Seishin plant in Kobe. The project features the installation of a fresh production line and a new warehouse, with completion targeted for 2028.
While the company did not specify which products the expansion would support, industry reports suggest the investment will bolster the manufacturing of high-demand diabetes and obesity medications. This follows a previous $44 million investment between 2022 and 2025 that introduced automated sorting machines and upgraded quality testing labs at the same facility.
A key link in the global supply chain
Established in 1981, the Seishin plant serves as Lilly’s only in-house manufacturing facility in Japan. This latest investment aims to promote digitalization and process optimization, allowing the firm to respond more flexibly to the rapid market uptake of its latest therapies, including tirzepatide and its Alzheimer’s drug, Kisunla.
Lilly’s move in Japan comes on the heels of a $3 billion commitment to local production in China and a $500 million investment to attract clinical trials to South Korea. Back in the U.S., the company continues a massive domestic infrastructure push, committing billions to new facilities in states like Pennsylvania and Texas to navigate potential shifts in international pharmaceutical trade policies.